Education
About Us
Working with TipRanks
Follow Us
Ocumension Therapeutics (HK:1477)
:1477
1477 Stock Chart & Stats
HK$7.55
-HK$0.01(-0.25%)
At close: 4:00 PM EST
HK$7.55
-HK$0.01(-0.25%)
Day’s Range― - ―
52-Week RangeHK$3.91 - HK$12.23
Previous CloseN/A
Volume1.11M
Average Volume (3M)3.41M
Market Cap
HK$5.71B
Enterprise ValueHK$4.74B
Total Cash (Recent Filing)HK$578.27M
Total Debt (Recent Filing)HK$83.22M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Mar 20, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding836,331,900
10 Day Avg. Volume1,456,522
30 Day Avg. Volume3,406,832
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)0.77
Price to Sales (P/S)6.97
P/FCF Ratio-7.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Revenue GrowthSustained top-line growth near +70% demonstrates strong market adoption of Ocumension's ophthalmic products and expanding commercial traction. Durable revenue expansion supports scale economics, funds continued R&D investment, and improves the company's ability to leverage fixed costs over the medium term.
Strong Balance Sheet / Low LeverageA conservatively capitalized balance sheet with minimal debt and very high equity ratio gives the company financial flexibility to fund trials and commercialization without immediate refinancing pressure. This reduces solvency risk and supports strategic options in a capital-intensive biotech industry.
Healthy Gross MarginA gross margin around 54% indicates efficient production and pricing power for core products. Solid unit economics create a structural buffer to absorb elevated R&D and SG&A spend, improving the company's ability to restore operating profitability as revenue continues to scale.
Bears Say
Sustained Net LossesDeep negative operating and net margins reflect that current revenues do not cover operating and development costs. Persistent losses erode retained capital, limit internal funding for growth, and increase reliance on external financing until the company can achieve sustainable positive margins.
Weak Operating Cash FlowLack of operating cash generation despite revenue growth indicates structural cash conversion issues. Ongoing negative or zero FCF forces dependence on equity or debt raises, which can dilute shareholders or increase leverage and constrain the company's ability to fund trials and commercialization autonomously.
Negative Return On EquityA negative ROE despite a high equity base shows shareholder capital is not producing returns. This signals inefficient capital allocation and raises questions about management's ability to translate investments into profits, potentially impairing long-term investor confidence and access to capital.
Ocumension Therapeutics News
1477 FAQ
What was Ocumension Therapeutics’s price range in the past 12 months?
Ocumension Therapeutics lowest stock price was HK$3.91 and its highest was HK$12.23 in the past 12 months.
What is Ocumension Therapeutics’s market cap?
Ocumension Therapeutics’s market cap is HK$5.71B.
When is Ocumension Therapeutics’s upcoming earnings report date?
Ocumension Therapeutics’s upcoming earnings report date is Mar 20, 2026 which is in 25 days.
How were Ocumension Therapeutics’s earnings last quarter?
Ocumension Therapeutics released its earnings results on Aug 21, 2025. The company reported -HK$0.192 earnings per share for the quarter, missing the consensus estimate of -HK$0.136 by -HK$0.057.
Is Ocumension Therapeutics overvalued?
According to Wall Street analysts Ocumension Therapeutics’s price is currently Overvalued.
Does Ocumension Therapeutics pay dividends?
Ocumension Therapeutics does not currently pay dividends.
What is Ocumension Therapeutics’s EPS estimate?
Ocumension Therapeutics’s EPS estimate is -0.08.
How many shares outstanding does Ocumension Therapeutics have?
Ocumension Therapeutics has 836,331,900 shares outstanding.
What happened to Ocumension Therapeutics’s price movement after its last earnings report?
Ocumension Therapeutics reported an EPS of -HK$0.192 in its last earnings report, missing expectations of -HK$0.136. Following the earnings report the stock price went up 5.268%.
Which hedge fund is a major shareholder of Ocumension Therapeutics?
Currently, no hedge funds are holding shares in HK:1477
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocumension Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.56%
12-Months-Change
Fundamentals
Return on Equity
-7.71%
Trailing 12-Months
Asset Growth
31.29%
Trailing 12-Months
Company Description
Ocumension Therapeutics
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company discovers, develops, and commercializes therapies for ophthalmic patients. It offers drugs for the treatment of blepharitis, infective and allergic conjunctivitis, dry eye, cataract, glaucoma and ocular hypertension, postoperative inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. As of December 31, 2021, the company had 20 drug assets in its portfolio. Ocumension Therapeutics was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.
Technical Analysis
Lepu Biopharma Co. Ltd. Class H
―
CStone Pharmaceuticals
―
Zhaoke Ophthalmology Ltd.
―
Shandong Boan Biotechnology Company., Limited. Class H
―
CK Life Sciences International (Holdings), Inc.
―
Options Prices
Currently, No data available
---